News Caris swells its planned IPO, seeking $5.7bn valuation AI-powered techbio firm Caris Life Sciences has raised the target price for its IPO, pointing to strong demand among investors.
News Update: Rumour confirmed as Lilly buys Verve Therapeutics Ahead of an opt-in decision on a PCSK9 inhibitor candidate, Eli Lilly is reported to be in advanced takeover negotiations with Verve Therapeutics.
News Genentech's Bittenbender named board chair at BIO Genentech's Fritz Bittenbender becomes chair of the Biotechnology Innovation Organization at a challenging time for the sector.
News After rebuffing Biogen, Sage pairs off with Supernus Sage Therapeutics has agreed to be acquired by Supernus Pharma in a deal valued at around $571 million.
News J&J says two drugs are better than one in pretreated myeloma Combining Johnson & Johnson's multiple myeloma therapies Talvey and Tecvayli shows promise in a hard-to-treat form of multiple myeloma.
News Former CEO wins bidding war for 23andMe, beating Regeneron 23andMe's co-founder and former chief executive, Anne Wojcicki, looks set to regain control of the genetic testing business.
News Gilead strikes again, penning $5bn deal to buy Tubulis Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
